The use of humidified high-flow nasal cannulae (HHFNC) as an alternative mode of non-invasive ventilation (NIV) in neonates has become widespread. A survey of UK neonatal units showed the proportion using HHFNC had increased from 56% in 2012 to 87% in 2015 (1) . A recently reported Cochrane Review (2) comparing the use of HHFNC against other NIV modes of ventilation immediately after birth or following extubation showed no significant difference in the rates of bronchopulmonary dysplasia (BPD) or death and no significant difference in the rates of treatment failure/reintubation. Benefits cited include a significantly reduced risk of nasal trauma as compared to continuous positive airway pressure (CPAP). Furthermore, both medical staff and parents (3) were found to prefer HHFNC to CPAP. Identification of infants in whom use of HHFNC as either a primary or step-down mode of respiratory support may be inappropriate might further reduce the failure rate of HHFNC.
We carried out a retrospective analysis of all infants treated with HHFNC admitted to the neonatal unit of King's College Hospital NHS Foundation Trust (London, UK) between 01/01/2015 and 31/12/2016. Our aim was to identify the clinical and demographic characteristics that might contribute to failure of support by HHFNC.
Failure was defined as the need to switch to CPAP or intubation and mechanical ventilation (MV) for recurrent episodes of apnoea, development of a respiratory acidosis (pH<7.25 and pCO2>8 kPa) or an inspired oxygen concentration (FiO2) requirement > 0.6. Success was defined as weaning off all respiratory support or weaning to supplemental oxygen delivered by low-flow nasal cannulae. In infants who had had multiple episodes of support using HHFNC, only the first episode was reviewed. The episode of HHFNC was defined as primary if HHFNC was the primary method of respiratory support used or a step-down episode if it was following from CPAP or MV.
Two hundred and twenty-six infants were identified from whom 134 complete records were available for use. Out of the 134, 32 infants failed HHFNC (Table 1) . Infants who failed HHFNC had a lower mean birth weight (p=0.035), higher mean FiO2 at time of commencing HHFNC (p=0.004) and a higher incidence of positive blood culture up to the time of starting HHFNC (p=0.001). They were also found to have a higher maximum flow rate at the time of starting HHFNC (p=0.004).
Multivariate regression analysis of birth weight, positive blood cultures and FiO2 using failure of HHFNC as the outcome showed that the mean FiO2 at the time of starting HHFNC was independently significantly higher in the infants who failed (p<0.05) but neither birth weight nor a positive blood culture were significantly different between the failure and success groups. A FiO2 > 28% predicted failure of HHFNC with a sensitivity of 73% and specificity of 61%. Our data suggest that failure of HHFNC therapy is more common in neonates with a higher FiO2 at the time of starting HHFNC. Arguably, a higher oxygen requirement reflects higher underlying lung disease severity as ventilation to perfusion mismatch and the degree of the intrapulmonary right to left shunting correlate with the oxygen requirement (4) . The importance of this study is that we report that a higher FiO2 on starting HHFNC is associated with failure of HHFNC. Manley et al undertook a secondary analysis of a randomized trial comparing HHFNC and CPAP and reached similar conclusions (5) . They, however, only used HHFNC as a primary mode of support at birth. In our study, we also assessed infants in whom HHFNC was used as a stepdown mode of support. We should acknowledge limitations of our study which were that records of only 59% of the eligible infants were available and it was a retrospective analysis of non-randomised data. Nevertheless, our results highlight a subgroup of infants who might be unlikely to benefit from HHFNC and may inform entry criteria into randomized trials. 
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